KR20140033283A - Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물 - Google Patents

Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물 Download PDF

Info

Publication number
KR20140033283A
KR20140033283A KR1020120099615A KR20120099615A KR20140033283A KR 20140033283 A KR20140033283 A KR 20140033283A KR 1020120099615 A KR1020120099615 A KR 1020120099615A KR 20120099615 A KR20120099615 A KR 20120099615A KR 20140033283 A KR20140033283 A KR 20140033283A
Authority
KR
South Korea
Prior art keywords
protein
fragment
fusion
seq
exon
Prior art date
Application number
KR1020120099615A
Other languages
English (en)
Korean (ko)
Inventor
서정선
김영태
주영석
김은희
강진형
Original Assignee
주식회사 마크로젠
서울대학교산학협력단
가톨릭대학교 산학협력단
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 주식회사 마크로젠, 서울대학교산학협력단, 가톨릭대학교 산학협력단 filed Critical 주식회사 마크로젠
Priority to KR1020120099615A priority Critical patent/KR20140033283A/ko
Priority to PCT/KR2013/008070 priority patent/WO2014038887A1/fr
Publication of KR20140033283A publication Critical patent/KR20140033283A/ko

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1825Fibroblast growth factor [FGF]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62DNA sequences coding for fusion proteins
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407Specifically defined cancers
    • G01N33/57423Specifically defined cancers of lung
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/136Screening for pharmacological compounds
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/178Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
KR1020120099615A 2012-09-07 2012-09-07 Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물 KR20140033283A (ko)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020120099615A KR20140033283A (ko) 2012-09-07 2012-09-07 Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
PCT/KR2013/008070 WO2014038887A1 (fr) 2012-09-07 2013-09-06 Protéine de fusion comprenant fgfr2 et composition de traitement du cancer la comprenant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020120099615A KR20140033283A (ko) 2012-09-07 2012-09-07 Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물

Publications (1)

Publication Number Publication Date
KR20140033283A true KR20140033283A (ko) 2014-03-18

Family

ID=50237419

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020120099615A KR20140033283A (ko) 2012-09-07 2012-09-07 Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물

Country Status (2)

Country Link
KR (1) KR20140033283A (fr)
WO (1) WO2014038887A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10370724B2 (en) 2014-07-17 2019-08-06 Blueprint Medicines Corporation PRKC fusions

Also Published As

Publication number Publication date
WO2014038887A1 (fr) 2014-03-13

Similar Documents

Publication Publication Date Title
AU2020270508B2 (en) C/EBP alpha short activating RNA compositions and methods of use
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
US11103538B2 (en) Targeting epigenetic regulators using a bacterial delivery system
US6262333B1 (en) Human genes and gene expression products
KR101234281B1 (ko) 염색체 안정화에 관한 유전자를 표적으로 하는 암세포 특이적 아포토시스 유도제
KR20180020125A (ko) 변형된 t 세포 및 이의 제조 및 사용 방법
KR20150129847A (ko) 융합 단백질 및 이들의 방법
KR20120082906A (ko) 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
KR20080043892A (ko) 단일 카피 게놈 교잡 프로브 및 이의 생성 방법
JP2003088388A (ja) 新規な全長cDNA
US20090305284A1 (en) Methods for Identifying Risk of Breast Cancer and Treatments Thereof
JP2003135075A (ja) 新規な全長cDNA
CN1704478A (zh) 评估急性髓性白血病患者的方法
KR20220054401A (ko) 감염의 숙주 rna 바이오마커의 신속한 조기-검출 및 인간의 covid-19 코로나바이러스 감염의 조기 식별을 위한 시스템, 방법 및 조성물
WO2021183218A1 (fr) Compositions et procédés de modulation de l'interaction entre l'oncoprotéine de fusion ss18-ssx et les nucléosomes
KR102039311B1 (ko) Axl을 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
AU2016202635B2 (en) Method for assessing embryotoxicity
JP2003159059A (ja) 痛みに関連する分子の同定及び使用
KR102661616B1 (ko) Gpr156 변이체 및 이들의 용도
CN115151558A (zh) 哺乳动物序列中的靶向整合增强基因表达
US20020137077A1 (en) Genes regulated in activated T cells
KR20140033283A (ko) Fgfr2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
KR20140033282A (ko) Ros1을 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
KR20140033617A (ko) Kras를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물
KR20140033618A (ko) Aplp2를 포함하는 융합 단백질 및 이를 포함하는 암 진단용 조성물

Legal Events

Date Code Title Description
N231 Notification of change of applicant
WITN Withdrawal due to no request for examination